These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 6502472)

  • 21. Disopyramide pharmacokinetics in patients with acute myocardial infarction.
    Pentikäinen PJ; Huikuri H; Jounela AJ; Wilen G
    Eur J Clin Pharmacol; 1985; 28(1):45-51. PubMed ID: 3987785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability.
    Bryson SM; Whiting B; Lawrence JR
    Br J Clin Pharmacol; 1978 Nov; 6(5):409-19. PubMed ID: 728284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of neglecting nonlinear plasma-protein binding on disopyramide bioavailability studies.
    Upton RA; Williams RL
    J Pharmacokinet Biopharm; 1986 Aug; 14(4):365-79. PubMed ID: 3772738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of urine pH and plasma protein binding on the renal clearance of disopyramide.
    Cunningham JL; Shen DD; Shudo I; Azarnoff DL
    Clin Pharmacokinet; 1977; 2(5):373-83. PubMed ID: 21054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of oral disopyramide phosphate in patients with renal impairment.
    Johnston A; Henry JA; Warrington SJ; Hamer NA
    Br J Clin Pharmacol; 1980 Sep; 10(3):245-8. PubMed ID: 7437241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disposition kinetics of disopyramide in human healthy volunteers described by an open three compartment model.
    Bonde J; Jensen NM; Pedersen LE; Angelo HR; Rasmussen SN; Trap-Jensen J; Kampmann JP
    Pharmacol Toxicol; 1989 May; 64(5):412-6. PubMed ID: 2771866
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and steady-state myocardial uptake of disopyramide in the dog.
    Karim A; Kook C; Novotney RL; Zagarella J; Campion J
    Drug Metab Dispos; 1978; 6(3):338-45. PubMed ID: 26556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stereoselective disposition and metabolism of disopyramide in pediatric patients.
    Echizen H; Takahashi H; Nakamura H; Ochiai K; Chiba K; Koike K; Ogata H; Ishizaki T
    J Pharmacol Exp Ther; 1991 Dec; 259(3):953-60. PubMed ID: 1762088
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elimination kinetics and urinary excretion of disopyramide in human healthy volunteers.
    Bonde J; Jensen NM; Pedersen LE; Graudal NA; Angelo HR; Kampmann JP
    Pharmacol Toxicol; 1988 May; 62(5):298-301. PubMed ID: 3413032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disposition kinetics of disopyramide in patients with renal insufficiency.
    Shen DD; Cunningham JL; Shudo I; Azarnoff DL
    Biopharm Drug Dispos; 1980; 1(3):133-40. PubMed ID: 7448340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of disopyramide in patients with chronic renal failure.
    Francois B; Mallein R; Rondelet J; Lussignol M
    Eur J Drug Metab Pharmacokinet; 1983; 8(1):85-92. PubMed ID: 6861798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disopyramide kinetics in renal impairment: determinants of interindividual variability.
    Burk M; Peters U
    Clin Pharmacol Ther; 1983 Sep; 34(3):331-40. PubMed ID: 6883909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonlinear pharmacokinetics of unbound propranolol after oral administration.
    Straka RJ; Lalonde RL; Pieper JA; Bottorff MB; Mirvis DM
    J Pharm Sci; 1987 Jul; 76(7):521-4. PubMed ID: 3668812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The influence of protein binding on disopyramide clearance.
    Bryson SM; Lawrence JR; Steele WH; Campbell BC; Elliott HL; Sumner DJ
    Eur J Clin Pharmacol; 1982; 23(5):453-6. PubMed ID: 7151851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between alpha 1-acid glycoprotein and plasma binding of disopyramide and mono-N-dealkyldisopyramide.
    Bredesen JE; Kierulf P
    Br J Clin Pharmacol; 1984 Nov; 18(5):779-84. PubMed ID: 6508986
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum disopyramide concentrations and suppression of ventricular premature contractions.
    Ueda CT; Dzindzio BS; Vosik WM
    Clin Pharmacol Ther; 1984 Sep; 36(3):326-36. PubMed ID: 6467792
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The stereoselective disposition of disopyramide in the dog.
    Giacomini KM; Giacomini JC; Swezey SE; Harrison DC; Nelson WL; Burke TR; Blaschke TF
    J Cardiovasc Pharmacol; 1980; 2(6):825-32. PubMed ID: 6160331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo interaction of the enantiomers of disopyramide in human subjects.
    Giacomini KM; Nelson WL; Pershe RA; Valdivieso L; Turner-Tamiyasu K; Blaschke TF
    J Pharmacokinet Biopharm; 1986 Aug; 14(4):335-56. PubMed ID: 3772736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immediate- versus controlled-release disopyramide: importance of saturable binding.
    Davies RF; Siddoway LA; Shaw L; Barbey JT; Roden DM; Woosley RL
    Clin Pharmacol Ther; 1993 Jul; 54(1):16-22. PubMed ID: 8330460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of altered disopyramide binding on its pharmacologic response in rabbits.
    Huang JD; Oie S
    J Pharmacol Exp Ther; 1982 Nov; 223(2):469-71. PubMed ID: 7131300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.